autologous G-CSF mobilized peripheral blood mononuclear cells

This autologous cell therapy, developed by Beike Biotech India (a subsidiary of Shenzhen Beike Biotechnology), utilizes peripheral blood mononuclear cells (PB-MNCs) mobilized from the patient's bone marrow into the peripheral blood using granulocyte colony-stimulating factor (G-CSF). Following mobilization and collection, the PB-MNCs are administered via multiple intramuscular injections into ischemic limbs. The therapy is primarily indicated for the treatment of diabetic limb ischemia, critical limb ischemia, and chronic ulcers, including diabetic foot and leg ulcers. Its mechanism of action involves therapeutic angiogenesis, which is promoted through the paracrine secretion of various growth factors and cytokines from the implanted cells. These factors stimulate the formation of collateral blood vessels and promote tissue regeneration, thereby improving blood perfusion and facilitating wound healing in patients with severe peripheral arterial disease.

Other names

G-CSF mobilized autologous PB-MNCsautologous PB-MNC therapyautologous peripheral blood mononuclear cell therapy